SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trega Biosciences (TRGA), formerly HPIP -- Ignore unavailable to you. Want to Upgrade?


To: bob zagorin who wrote (91)2/9/2000 10:10:00 AM
From: bob zagorin  Respond to of 152
 
Sturza's Research Team chose the following 10 companies for
inclusion in its annual "Year-End Stock Basket". For the period of
December 3, 1999 to February 8, 2000, these recommendations
appreciated an average of 136.7%; by comparison, the Nasdaq Biotech
Index (CXBT.NASDAQ) increased 73.2% during the same time period.

Rec'd 2/8/00
Company Ticker Price Price %Change

Aradigm ARDM $6.63 $24.25 266.0%
Discovery Labs DSCO 1.56 5.38 244.5%
Trega Biosci TRGA 1.31 4.13 214.9%
Genset GENXY 10.50 9.13 177.4%
Questcor Pharm QSC 1.25 2.75 120.0%
Magainin Pharm MAGN 1.88 3.72 98.4%
Synaptic Pharm SNAP 4.59 8.75 90.6%
GelTex Pharm GELX 10.13 19.13 88.8%
Draxis Health DRAX 1.16 1.69 45.7%
Scios SCIO 4.56 5.50 20.6%
Average 136.7%
*T
-0-

Published 50 times a year, Sturza's Medical Investment Letter is
a leader in providing timely, objective research on the biotechnology,
pharmaceutical and medical device sectors to investors worldwide.
Sturza's Medical Investment Letter, Sturza's Institutional Research
(in-depth technology assessments for institutional investors) and
Ursus Capital (a hedge fund specializing in medical technology
investments) are a family of companies dedicated to independent
medical technology research and investment management.

CONTACT:

Sturza's Medical Research

Doris Durfee, 212/541-8200

e-mail: info@sturzas.com

website: www.sturzas.com